Based on their safety profile, with emphasis on renal safety, the risk for urinary tract infections and for DKA, the use of SGLT-2 inhibitors as adjunct diuretics in the setting of acute HF should not be discouraged, especially if the patients do not respond to first-line treatment options. The gene discussed is SLC5A2; the disease is urinary tract infection.